Observational Trial of Cardiotoxicity in Patients Undergoing Chemotherapy. (PROMETEY)

  • End date
    Jun 28, 2024
  • participants needed
  • sponsor
    Moscow State University of Medicine and Dentistry
Updated on 15 February 2022
renal function
total bilirubin
absolute neutrophil count
heart failure
myocardial infarction
myocardial injury
cancer treatment
sudden cardiac death
dilated cardiomyopathy
heart transplantation
myocardial dysfunction


Advances in treatment have led to improved survival of patients with cancer, but have also increased morbidity and mortality due to cancer treatment side effects. Cardiotoxicity is one the most frequent side effect which may lead to premature morbidity and death among cancer survivors. The most concerning cardiovascular complications of cancer therapy is myocardial dysfunction, leading to heart failure, and fatal arrhythmias, especially those induced by QT-prolonging drugs.

PROMETEY (PROspective Multidisciplinary obsErvational Trial of cardiotoxicity in patiEnts undergoing anticancer therapy) - is Russian multicenter observational study assessing cardiotoxicity and its clinical, biochemical and genetic factors in patients on cancer therapy.

The objectives of the study are:

  • to reveal prevalence of cardiotoxic effects of cancer therapy in routine clinical practice in Russian Federation,
  • to assess contribution of these effects to mortality of patients on cancer therapy,
  • to evaluate clinical and economic consequences of cardiotoxicity in patients with cancer,
  • to develop an individualized model of cardiotoxicity risk factors based on clinical and laboratory parameters.

Patients: 400 cancer patients with toxic cardiomyopathy and 100 patients with idiopathic or family dilated cardiomyopathy.

Study duration: 60 months. All patients will undergo complex examination after signing informed consent form(ICF): physical exam, echocardiography with speckle tracking analysis, ambulatory 48-hours ECG monitoring, biochemistry, analysis of biomarkers of myocardial injury, fibrosis and inflammation.

Primary endpoint: all-cause mortality, heart transplantation, cardioverter-defibrillator implantation, hospitalization with heart failure decompensation.

Secondary endpoints:

  • thromboembolism,
  • fatal/ nonfatal myocardial infarction, stroke,
  • sudden cardiac death,
  • surgical therapy of heart failure or arrhythmias,
  • cardiovascular death,
  • all-cause mortality,
  • heart transplantation,
  • cardioverter-defibrillator implantation.

Condition Cardiotoxicity, Heart Failure, Dilated Cardiomyopathy
Treatment Echocardiography with speckle tracking analysis., 48-hour ECG monitoring., Blood samples analysis.
Clinical Study IdentifierNCT04055636
SponsorMoscow State University of Medicine and Dentistry
Last Modified on15 February 2022


Yes No Not Sure

Inclusion Criteria

written informed consent form (ICF)
Eastern Cooperative Oncology Group (ECOG) scale 0-3
patients with verified cancer on or planned to be on chemotherapy including anthracyclines
sufficient bone marrow function, including: absolute neutrophils > 1.5 _10^9/l, platelets > 100_10^9/l, hemoglobin > 9 g/dl
sufficient liver function, including: total bilirubin < 1.5upper normal value, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 upper normal value
sufficient renal function, including: creatinine clearance > 50 ml/min
For control group
verified non-toxic dilated cardiomyopathy

Exclusion Criteria

refusal of patient
coma, delirium
mental disorders
left chest radiation therapy
metastases in central nervous system
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note